This Startup Wants to Zap Your Gut to Treat Diabetes

Existing investors piled back in too: Hatteras Venture Partners, Lumira Ventures, Orlando Health Ventures, and (notably) Intuitive Ventures, the investment arm of the company behind the da Vinci surgical robot. When the people who revolutionized robotic surgery are writing checks, you pay attention.

This $50 million is actually an extension of a prior $88 million Series C from June 2024, bringing the total Series C haul to $138 million. That's a lot of conviction for a company with no product on the market yet.

The Trial That Will Make or Break Them

All of that cash is pointed at one thing: completing the ReCET Clinical Study. This is the big one, the pivotal trial that will determine whether the FDA lets them sell the device.

The trial design is about as rigorous as it gets. It's multicenter (up to 40 sites across the U.S. and Australia), randomized, double-blinded, and sham-controlled. That last part is key. Sham-controlled means some patients will undergo a fake version of the procedure, so researchers can tease apart the placebo effect from real results. It's the gold standard for device trials, and it's expensive to run; which explains why they need $138 million.

Enrollment has been underway since October 2024, after the FDA granted an Investigational Device Exemption in late 2023. CEO Stacey Pugh (formerly of Medtronic and Butterfly Network) framed the funding as a finish line in sight: "This financing puts us in a strong position to complete our pivotal study and take the ReCET System through FDA approval."

Her ambition goes beyond symptom management. "By restoring the duodenum to a healthier state, we aim to help patients do more than manage their symptoms," she said. "We want to potentially alter their disease progression."

They're Not the Only Ones Betting on the Gut

Endogenex isn't operating in a vacuum. Fractyl Health has been developing a similar concept called Revita, which uses hot water (hydrothermal ablation) instead of electrical pulses to resurface the duodenal lining. Fractyl's data looks promising: improved insulin sensitivity and benefits that persist up to two years.

So why does Endogenex think their approach is better? The non-thermal angle is the key differentiator. Using electricity instead of heat could mean more precise tissue targeting and fewer complications; though that's exactly what the pivotal trial needs to prove. Fractyl has a head start on clinical data, but Endogenex's pulsed-field technology represents a newer generation of the concept.

It's a bit like the early streaming wars. Fractyl got to market first (think Netflix), but Endogenex is betting its technology is fundamentally better (the Disney+ play). Whether that bet pays off depends entirely on the trial results.

Why This Matters Beyond One Company

Zoom out, and the bigger story here is about a philosophical shift in how we treat type 2 diabetes. For decades, the answer has been drugs: metformin, then sulfonylureas, then GLP-1 agonists like Ozempic and Mounjaro. These work, but they require ongoing use. Stop taking them, and the benefits fade.

A one-time procedure that resets your metabolic wiring? That's a fundamentally different value proposition. It's the difference between renting and owning.

With hundreds of millions of people living with diabetes worldwide (the vast majority being type 2), even a modest slice of that population represents an enormous market. And emerging research suggests that duodenal inflammation plays a role in disease progression that current drugs simply don't address.

Of course, we've been here before. Promising device-based approaches to metabolic disease have fizzled in the past. The sham-controlled trial is the ultimate truth serum, and plenty of exciting therapies have crumbled when tested against a convincing placebo.

But $138 million says some very smart people think this one's different. The next couple of years will tell us if they're right.

The Drug That Finally Cracked the Brain's Toughest Bouncer

For nearly 20 years, kids with Hunter syndrome had a treatment that couldn't reach their brains. Denali Therapeutics just got FDA approval for Avlayah, the first enzyme therapy that crosses the blood-brain barrier, and it could change the game for rare neurological diseases.